🔔 📢 The Cancer Drug Development Forum (CDDF) held a live webinar on “EU HTA Regulation.” on 12 March at 17:00 CET. This webinar featured a lively discussion between Michael Berntgen (EMA, NL), Niklas Hedberg (TLV, SE) and Dr. Vanessa Schaub (Roche, CH). Dr. Rosa Giuliani (Guy’s and St Thomas’ NHS Foundation Trust, UK) and Dr. Christian Schneider (Cencora PharmaLex, UK) moderated this webinar. Here are key takeaways from the webinar:
-
- Key experts in the field highlighted the milestones achieved so far in making the HTA Regulation a reality, especially with a view to Joint Clinical Assessment (JCA) and Joint Consultations. It was highlighted that the Regulation, and all Guidelines flowing from it, are respecting the distinct roles of regulators and health technology assessors.
- The Regulation has a huge potential to join up access to medicines for patients across Europe.
- There are numerous myths around it; one important to debunk is that there is no new assessment or principle introduced, i.e., there will not be an extra burden or requirement. But the Regulation aims at facilitating, simplifying and joining up.
- There is a clear agenda for opportunities by all involved stakeholders, with awareness, willingness and momentum to tackle any challenge awaiting when making the Regulation a reality.
🔶To watch the recording of the webinar, click the link: https://youtu.be/N4URvq7XvG4
🔶For speaker presentations, visit the CDDF website: https://cddf.org/events/past-events/cddf-meetings-2025/cddf-live-webinar-eu-hta-regulation/